NEWAMSTERDAM PHARMA CO NV (NAMS) saw its stock price soar 5.31% during intraday trading on Friday.
The surge followed a positive analyst update from Guggenheim, where analyst Debjit Chattopadhyay maintained a Buy rating on the company and set a price target of $45.00, likely boosting investor confidence.